We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Alpha emitter isotopes and PSMA ligands: the near future therapeutic prospective for castration-resistant prostate cancer.
- Authors
Volpe, Fabio; Piscopo, Leandra; Zampella, Emilia; Klain, Michele
- Abstract
A recent study published in the European Journal of Nuclear Medicine & Molecular Imaging explores the potential of alpha emitter isotopes and PSMA ligands as a therapeutic option for castration-resistant prostate cancer (CRPC). The study focuses on the use of 225-Actinium (225Ac) and its positive outcomes in patients with CRPC. The results show improved overall survival and radiological progression-free survival in patients treated with 225Ac-PSMA-617, even in those who were refractory to previous treatments. Further research is needed to standardize treatment protocols and enhance outcomes for patients with CRPC.
- Subjects
CASTRATION-resistant prostate cancer; ANDROGEN receptors; ISOTOPES
- Publication
European Journal of Nuclear Medicine & Molecular Imaging, 2024, Vol 51, Issue 5, p1207
- ISSN
1619-7070
- Publication type
Article
- DOI
10.1007/s00259-023-06574-w